Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Neoplasms"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Recruitment+Status%3A+Active%2C+not+recruiting%22&type=Subject&filter%5B%5D=topic_facet%3A%22Neoplasms%22
/vufind/Search/Results?lookfor=%22Recruitment+Status%3A+Active%2C+not+recruiting%22&type=Subject&filter%5B%5D=topic_facet%3A%22Neoplasms%22
Search /vufind/Search2/Results?lookfor=%22Recruitment+Status%3A+Active%2C+not+recruiting%22&type=Subject&filter%5B%5D=topic_facet%3A%22Neoplasms%22
PubPharm (943)
1
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers : Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
2
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation : Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
3
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors : A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
4
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery : A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
5
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors : Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
6
A Monotherapy in Subjects With Advanced Solid Tumors : A Phase I Study of the Safety, Tolerability, Pharmacokinetics Profiles and Preliminary Efficacy of 3D185 Monotherapy in Subjects With Advanced Solid Tumors
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
7
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer : BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
8
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies : Open-label, Dose-escalation Trial to Evaluate the Safety and Pharmacokinetics of GEN1046 in Japanese Subjects With Advanced Solid Malignancies
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
9
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO : A Phase II Open-Label Study for the Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation in BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a Homologous Recombination Deficiency
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
10
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy : First-in-Human, Open-label, Dose-Escalation Trial With an Expansion Cohort to Evaluate the Safety of GEN1053 as Monotherapy in Subjects With Malignant Solid Tumors
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[95]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Neoplasms
Medienart
943
Aufsätze
943
E-Artikel
943
E-Ressourcen
Zeitschriftentitel
943
ClinicalTrials.gov
Thema
943
610
Neoplasms
943
Recruitment Status: Active, not recruiting
849
Study Type: Interventional
307
Phase: Phase 1
233
Phase: Phase 2
116
Phase: Phase 1, Phase 2
101
Lymphoma
95
Carcinoma
94
Study Type: Observational
86
Recurrence
71
Breast Neoplasms
55
Hematologic Neoplasms
51
Multiple Myeloma
47
Sarcoma
45
Brain Neoplasms
45
Lung Neoplasms
41
Melanoma
39
Central Nervous System Neoplasms
39
Colorectal Neoplasms
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
938
2020-
5
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
943
Englisch
Haven't found what you're looking for?
Wird geladen...